{"transactions":[{"id":737416,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":38032,"kind":"person","name":"Moore David Scott","position":1,"cik":"0002088466","reported_name":"Moore David Scott","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:12:29.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000223","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071726000223/form4.xml","form_type":"4"}},{"id":737415,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":38032,"kind":"person","name":"Moore David Scott","position":1,"cik":"0002088466","reported_name":"Moore David Scott","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-15T21:12:29.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":21700,"price":11.5316,"value":250235.72,"ownership":{"direct":true},"balance_after":21700,"source":{"system":"sec-edgar","filing":"0001610717-26-000223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071726000223/form4.xml","form_type":"4"}},{"id":737554,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:10:06.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000222","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000161071726000222/form4.xml","form_type":"4"}},{"id":737679,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:08:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000221","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071726000221/form4.xml","form_type":"4"}},{"id":737551,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:06:45.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP.  As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000220","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071726000220/form4.xml","form_type":"4"}},{"id":737690,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":38136,"kind":"person","name":"van den Broek Richard","position":1,"cik":"0001431872","reported_name":"van den Broek Richard","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:04:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000219","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431872/000161071726000219/form4.xml","form_type":"4"}},{"id":770448,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-20T20:12:25.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":1932,"price":12.01,"value":23203.32,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1195035,"source":{"system":"sec-edgar","filing":"0001610717-26-000160","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071726000160/form4.xml","form_type":"4"}},{"id":770447,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-20T20:12:25.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":12.05,"value":60250.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1193103,"source":{"system":"sec-edgar","filing":"0001610717-26-000160","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071726000160/form4.xml","form_type":"4"}},{"id":799944,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":51149,"kind":"person","name":"Chan Andrew C.","position":1,"cik":"0002131504","reported_name":"Chan Andrew C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-27T21:32:20.000Z","date":"2026-04-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 23, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":16.02,"expiration_date":"2036-04-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001610717-26-000149","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071726000149/form4.xml","form_type":"4"}},{"id":926838,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.12,"expiration_date":"2024-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926837,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926836,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926835,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.965,"expiration_date":"2032-08-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926834,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.9899,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926833,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.6,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926832,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926831,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.27,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926830,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926829,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.61,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926828,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":12.5,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926827,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":9.7,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926826,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2026-03-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926825,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.12,"value":31800.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":210000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926824,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":1.64,"value":24600.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":195000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926823,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.49,"value":37350.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926822,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.965,"value":14475.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":165000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926821,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.9899,"value":14848.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926820,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.6,"value":39000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926819,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.74,"value":41100.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":120000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926818,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":3.27,"value":49050.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":105000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926817,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926816,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":3.61,"value":54150.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926815,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":12.5,"value":187500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926814,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":9.7,"value":145500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926813,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":15,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":977294,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-08T21:23:09.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":400000,"derivative":{"exercise_price":8.81,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001610717-25-000412","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071725000412/form4.xml","form_type":"4"}},{"id":978053,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-08T21:22:35.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":1000000,"derivative":{"exercise_price":8.81,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001610717-25-000411","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071725000411/form4.xml","form_type":"4"}},{"id":977833,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72078,"kind":"person","name":"Arcara Jeffrey","position":1,"cik":"0002010430","reported_name":"Arcara Jeffrey","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-08T16:22:04.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":8.81,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001610717-25-000410","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2010430/000161071725000410/form4.xml","form_type":"4"}},{"id":978189,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72117,"kind":"person","name":"LEA LEIV","position":1,"cik":"0000939012","reported_name":"LEA LEIV","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-08T16:21:35.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":400000,"derivative":{"exercise_price":8.81,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001610717-25-000409","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939012/000161071725000409/form4.xml","form_type":"4"}},{"id":1022809,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":38032,"kind":"person","name":"Moore David Scott","position":1,"cik":"0002088466","reported_name":"Moore David Scott","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-06T20:34:34.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from October 2, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":7.04,"expiration_date":"2035-10-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001610717-25-000360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071725000360/form4.xml","form_type":"4"}},{"id":1098293,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-07-02T01:23:37.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":false,"shares":1397684,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"exercise_date":"2025-04-29","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-25-000636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000636/ownership.xml","form_type":"4"}},{"id":1098292,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:23:37.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":1176332,"price":4.1586,"value":4891894.2552,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 27, 2025, OrbiMed Private Investments V, LP (\"OPI V\") exercised common warrants (\"Warrants\") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7165006,"source":{"system":"sec-edgar","filing":"0000947871-25-000636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000636/ownership.xml","form_type":"4"}},{"id":1098291,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:23:37.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":true,"shares":1397684,"price":3.5,"value":4891894.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8341338,"source":{"system":"sec-edgar","filing":"0000947871-25-000636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000636/ownership.xml","form_type":"4"}},{"id":1097639,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-07-02T01:17:05.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":false,"shares":1397684,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"exercise_date":"2025-04-29","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-25-000635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787125000635/ownership.xml","form_type":"4"}},{"id":1097638,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:17:05.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":1176332,"price":4.1586,"value":4891894.2552,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 27, 2025, OrbiMed Private Investments V, LP (\"OPI V\") exercised common warrants (\"Warrants\") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7165006,"source":{"system":"sec-edgar","filing":"0000947871-25-000635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787125000635/ownership.xml","form_type":"4"}},{"id":1097637,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:17:05.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":true,"shares":1397684,"price":3.5,"value":4891894.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8341338,"source":{"system":"sec-edgar","filing":"0000947871-25-000635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787125000635/ownership.xml","form_type":"4"}},{"id":1109683,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:28:00.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000233","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071725000233/form4.xml","form_type":"4"}},{"id":1109538,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:27:33.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000232","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000161071725000232/form4.xml","form_type":"4"}},{"id":1109408,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:27:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000231","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071725000231/form4.xml","form_type":"4"}},{"id":1109516,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:26:41.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000230","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071725000230/form4.xml","form_type":"4"}},{"id":1119140,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Warrant (Right to Buy)","published_at":"2025-06-06T20:26:07.000Z","date":"2025-06-04","kind":"exercise","planned":false,"acquired":false,"shares":19357,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312 per share."}],"balance_after":0,"derivative":{"exercise_price":3.5,"exercise_date":"2024-05-06","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":19357},"source":{"system":"sec-edgar","filing":"0001610717-25-000174","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071725000174/form4.xml","form_type":"4"}},{"id":1119139,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-06T20:26:07.000Z","date":"2025-06-04","kind":"exercise","planned":false,"acquired":true,"shares":19357,"price":3.5,"value":67749.5,"ownership":{"direct":true},"balance_after":173130,"source":{"system":"sec-edgar","filing":"0001610717-25-000174","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071725000174/form4.xml","form_type":"4"}},{"id":1154100,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-05-09T20:09:21.000Z","date":"2025-05-07","kind":"exercise","planned":false,"acquired":false,"shares":559073,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312."}],"balance_after":0,"derivative":{"exercise_price":3.5,"exercise_date":"2024-05-06","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":559073},"source":{"system":"sec-edgar","filing":"0001610717-25-000115","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071725000115/form4.xml","form_type":"4"}},{"id":1154099,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-09T20:09:21.000Z","date":"2025-05-07","kind":"exercise","planned":false,"acquired":true,"shares":559073,"price":3.5,"value":1956755.5,"ownership":{"direct":true},"balance_after":1136707,"source":{"system":"sec-edgar","filing":"0001610717-25-000115","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071725000115/form4.xml","form_type":"4"}},{"id":1174638,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":38136,"kind":"person","name":"van den Broek Richard","position":1,"cik":"0001431872","reported_name":"van den Broek Richard","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-09T21:26:56.000Z","date":"2025-04-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 8, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-04-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001610717-25-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431872/000161071725000098/form4.xml","form_type":"4"}},{"id":1322570,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T21:39:46.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":4.99,"expiration_date":"2034-12-20","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001610717-24-000552","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071724000552/form4.xml","form_type":"4"}},{"id":1323259,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T21:38:43.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":750000,"derivative":{"exercise_price":4.99,"expiration_date":"2034-12-20","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001610717-24-000550","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071724000550/form4.xml","form_type":"4"}},{"id":1323082,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72078,"kind":"person","name":"Arcara Jeffrey","position":1,"cik":"0002010430","reported_name":"Arcara Jeffrey","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T16:40:19.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.99,"expiration_date":"2034-12-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001610717-24-000553","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2010430/000161071724000553/form4.xml","form_type":"4"}},{"id":1323390,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72117,"kind":"person","name":"LEA LEIV","position":1,"cik":"0000939012","reported_name":"LEA LEIV","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T16:39:11.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":4.99,"expiration_date":"2034-12-20","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001610717-24-000551","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939012/000161071724000551/form4.xml","form_type":"4"}},{"id":1477168,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:46:29.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000345","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071724000345/form4.xml","form_type":"4"}},{"id":1476990,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:48:32.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000344","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000161071724000344/form4.xml","form_type":"4"}},{"id":1476837,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:44:55.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000342","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071724000342/form4.xml","form_type":"4"}},{"id":1476982,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:41:58.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to an agreement with Advisors and GP V, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000340","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071724000340/form4.xml","form_type":"4"}},{"id":1477288,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":89833,"kind":"person","name":"Gould Terry P","position":1,"cik":"0001553470","reported_name":"Gould Terry P","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T16:43:24.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This option was granted to Elisha P. Gould, a director of Corvus Pharmaceuticals, Inc., who is a partner of Adams Street Partners, LLC. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the Funds. By agreement with the Funds, Mr. Gould is deemed to hold the option for the benefit of the Funds. The option may be deemed to be indirectly beneficially owned by Adams Street Partners, LLC. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), disclaim beneficial ownership of the option except to the extent of the pecuniary interest therein."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000341","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553470/000161071724000341/form4.xml","form_type":"4"}},{"id":1517929,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-14T21:02:49.000Z","date":"2024-05-10","kind":"gift","planned":false,"acquired":false,"shares":302016,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1188103,"source":{"system":"sec-edgar","filing":"0001610717-24-000237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071724000237/form4.xml","form_type":"4"}},{"id":1523075,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2024-05-09T00:34:00.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1397684,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of $1.7311."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with OrbiMed Advisors and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with OrbiMed Advisors and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1397684,"derivative":{"exercise_price":3.5,"underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-24-000451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787124000451/ownership.xml","form_type":"4"}},{"id":1523074,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2024-05-09T00:34:00.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1444085,"price":1.7311,"value":2499855.5435,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1444085,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1444085},"source":{"system":"sec-edgar","filing":"0000947871-24-000451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787124000451/ownership.xml","form_type":"4"}},{"id":1523649,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2024-05-09T00:28:59.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1397684,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of $1.7311."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1397684,"derivative":{"exercise_price":3.5,"underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-24-000450","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000450/ownership.xml","form_type":"4"}},{"id":1523648,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2024-05-09T00:28:59.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1444085,"price":1.7311,"value":2499855.5435,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1444085,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1444085},"source":{"system":"sec-edgar","filing":"0000947871-24-000450","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000450/ownership.xml","form_type":"4"}},{"id":1524360,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Warrant (Right to Buy)","published_at":"2024-05-07T21:06:34.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":19357,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312."}],"balance_after":19357,"derivative":{"exercise_price":3.5,"exercise_date":"2024-05-06","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":19357},"source":{"system":"sec-edgar","filing":"0001610717-24-000232","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071724000232/form4.xml","form_type":"4"}},{"id":1524359,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-07T21:06:34.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.7312,"value":34624.0,"ownership":{"direct":true},"balance_after":153773,"source":{"system":"sec-edgar","filing":"0001610717-24-000232","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071724000232/form4.xml","form_type":"4"}},{"id":1525048,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2024-05-07T21:05:52.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":559073,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312."}],"balance_after":559073,"derivative":{"exercise_price":3.5,"exercise_date":"2024-05-06","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":559073},"source":{"system":"sec-edgar","filing":"0001610717-24-000231","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071724000231/form4.xml","form_type":"4"}},{"id":1525047,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-07T21:05:52.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":577634,"price":1.7312,"value":999999.9808,"ownership":{"direct":true},"balance_after":577634,"source":{"system":"sec-edgar","filing":"0001610717-24-000231","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071724000231/form4.xml","form_type":"4"}},{"id":1607686,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72078,"kind":"person","name":"Arcara Jeffrey","position":1,"cik":"0002010430","reported_name":"Arcara Jeffrey","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-01T17:57:04.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from February 2, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":400000,"derivative":{"exercise_price":2.3,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001610717-24-000106","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2010430/000161071724000106/form4.xml","form_type":"4"}},{"id":1718155,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:09:02.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001610717-23-000395","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000161071723000395/form4.xml","form_type":"4"}},{"id":1717433,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:07:24.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001610717-23-000392","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071723000392/form4.xml","form_type":"4"}},{"id":1717712,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:05:43.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000390","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071723000390/form4.xml","form_type":"4"}},{"id":1717595,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:04:39.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000389","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000161071723000389/form4.xml","form_type":"4"}},{"id":1717432,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:03:53.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000388","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071723000388/form4.xml","form_type":"4"}},{"id":1717582,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:02:31.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000386","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071723000386/form4.xml","form_type":"4"}},{"id":1718325,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72117,"kind":"person","name":"LEA LEIV","position":1,"cik":"0000939012","reported_name":"LEA LEIV","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T16:08:13.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001610717-23-000394","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939012/000161071723000394/form4.xml","form_type":"4"}},{"id":1717836,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":107654,"kind":"person","name":"Mitchell Edith P.","position":1,"cik":"0001484982","reported_name":"Mitchell Edith P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T16:06:11.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000391","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484982/000161071723000391/form4.xml","form_type":"4"}},{"id":1717846,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":89833,"kind":"person","name":"Gould Terry P","position":1,"cik":"0001553470","reported_name":"Gould Terry P","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T16:03:11.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This option was granted to Elisha P. Gould, a director of Corvus Pharmaceuticals, Inc., who is a partner of Adams Street Partners, LLC. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the Funds. By agreement with the Funds, Mr. Gould is deemed to hold the option for the benefit of the Funds. The option may be deemed to be indirectly beneficially owned by Adams Street Partners, LLC. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), disclaim beneficial ownership of the option except to the extent of the pecuniary interest therein."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000387","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553470/000161071723000387/form4.xml","form_type":"4"}},{"id":1849045,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:03:54.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000189","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071723000189/form4.xml","form_type":"4"}},{"id":1849067,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:00:23.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000187","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000161071723000187/form4.xml","form_type":"4"}},{"id":1848739,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:59:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000186","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071723000186/form4.xml","form_type":"4"}},{"id":1849368,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:58:17.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000185","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071723000185/form4.xml","form_type":"4"}},{"id":1849502,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":89833,"kind":"person","name":"Gould Terry P","position":1,"cik":"0001553470","reported_name":"Gould Terry P","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T17:01:49.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This option was granted to Elisha P. Gould, a director of Corvus Pharmaceuticals, Inc., who is a partner of Adams Street Partners, LLC. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the Funds. By agreement with the Funds, Mr. Gould is deemed to hold the option for the benefit of the Funds. The option may be deemed to be indirectly beneficially owned by Adams Street Partners, LLC. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), disclaim beneficial ownership of the option except to the extent of the pecuniary interest therein."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000188","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553470/000161071723000188/form4.xml","form_type":"4"}},{"id":1849491,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":107654,"kind":"person","name":"Mitchell Edith P.","position":1,"cik":"0001484982","reported_name":"Mitchell Edith P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T16:57:29.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000184","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484982/000161071723000184/form4.xml","form_type":"4"}},{"id":1891361,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-16T20:54:08.000Z","date":"2023-05-15","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.45,"value":24500.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001610717-23-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071723000041/form4.xml","form_type":"4"}},{"id":1932861,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-03T20:30:37.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from March 31, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":800000,"derivative":{"exercise_price":0.91,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001140361-23-015800","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000114036123015800/form4.xml","form_type":"4"}},{"id":2079422,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72052,"kind":"person","name":"Jones William Benton","position":1,"cik":"0001664506","reported_name":"Jones William Benton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-20T23:22:25.000Z","date":"2022-12-20","kind":"purchase","acquired":true,"shares":20000,"price":0.79,"value":15800.0,"ownership":{"direct":true},"balance_after":133773,"source":{"system":"sec-edgar","filing":"0001567619-22-021876","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761922021876/doc1.xml","form_type":"4"}},{"id":2085428,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-15T21:32:20.000Z","date":"2022-12-14","kind":"purchase","acquired":true,"shares":10000,"price":0.7812,"value":7812.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.7798 to $0.7899, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1490119,"source":{"system":"sec-edgar","filing":"0001567619-22-021650","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000156761922021650/doc1.xml","form_type":"4"}},{"id":2085427,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-15T21:32:20.000Z","date":"2022-12-13","kind":"purchase","acquired":true,"shares":50000,"price":0.7403,"value":37015.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.73 to $0.7580, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 35,714 shares previously held directly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1480119,"source":{"system":"sec-edgar","filing":"0001567619-22-021650","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000156761922021650/doc1.xml","form_type":"4"}},{"id":2085623,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72117,"kind":"person","name":"LEA LEIV","position":1,"cik":"0000939012","reported_name":"LEA LEIV","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-15T16:33:15.000Z","date":"2022-12-14","kind":"purchase","acquired":true,"shares":4000,"price":0.841,"value":3364.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Leiv Lea IRA Contributory."}],"balance_after":133238,"source":{"system":"sec-edgar","filing":"0001567619-22-021651","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939012/000156761922021651/doc1.xml","form_type":"4"}},{"id":2085622,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":72117,"kind":"person","name":"LEA LEIV","position":1,"cik":"0000939012","reported_name":"LEA LEIV","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-15T16:33:15.000Z","date":"2022-12-13","kind":"purchase","acquired":true,"shares":30000,"price":0.7425,"value":22275.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.7255 to $0.7806, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Leiv Lea IRA Contributory."}],"balance_after":129238,"source":{"system":"sec-edgar","filing":"0001567619-22-021651","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939012/000156761922021651/doc1.xml","form_type":"4"}},{"id":2150068,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-28T21:45:16.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":25000,"price":0.7628,"value":19070.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.7425 to $0.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1394405,"source":{"system":"sec-edgar","filing":"0001567619-22-017917","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000156761922017917/doc1.xml","form_type":"4"}},{"id":2154303,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-20T22:58:39.000Z","date":"2022-09-20","kind":"purchase","acquired":true,"shares":5000,"price":0.815,"value":4075.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1369405,"source":{"system":"sec-edgar","filing":"0001567619-22-017639","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000156761922017639/doc1.xml","form_type":"4"}},{"id":2154302,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-20T22:58:39.000Z","date":"2022-09-20","kind":"purchase","acquired":true,"shares":2700,"price":0.82,"value":2214.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1364405,"source":{"system":"sec-edgar","filing":"0001567619-22-017639","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000156761922017639/doc1.xml","form_type":"4"}},{"id":2154301,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":45769,"kind":"person","name":"MILLER RICHARD A MD","position":1,"cik":"0001031847","reported_name":"MILLER RICHARD A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-20T22:58:39.000Z","date":"2022-09-20","kind":"purchase","acquired":true,"shares":12300,"price":0.8101,"value":9964.23,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the \"Miller-Horning Trust\"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust."}],"balance_after":1361705,"source":{"system":"sec-edgar","filing":"0001567619-22-017639","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031847/000156761922017639/doc1.xml","form_type":"4"}}],"next_cursor":"2022-09-20T22:58:39.000000Z,2154301"}